Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

Phase 3LAM561Positive

AI Analysis

Summary

Laminar Pharma announced completion of the last patient visit in its Phase 2b/3 trial for LAM561 in newly diagnosed glioblastoma patients. The milestone indicates the trial enrollment and patient follow-up phase is complete, with results expected in the coming months.

Clinical Trial Data

Phase

2b/3

Outcome Details

Last patient, last visit completed in Phase 2b/3 trial

Importance:6/10

Sentiment:

0.50

glioblastomaPhase 2b/3clinical trialLPLVoncology

Read the original article

Published by PR Newswire Pharma on July 24, 2026 1:30 AM

Read Original